Stage IV Breast Cancer Clinical Trial
Official title:
A Phase II Trial Of Gemcitabine And Triapine In Refractory Metastatic Breast Cancer
Phase II trial to study the effectiveness of combining 3-AP with gemcitabine in treating patients who have refractory metastatic breast cancer. Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining 3-AP with gemcitabine may kill more tumor cells
Status | Terminated |
Enrollment | 68 |
Est. completion date | |
Est. primary completion date | June 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed breast cancer - Refractory metastatic disease - Measurable disease - At least 1 unidimensionally measurable lesion = 20 mm by conventional techniques OR = 10 mm by spiral CT scan - Must have received 1, and only 1, prior chemotherapy regimen for metastatic disease - Patients overexpressing HER2/neu antigen must have received a prior trastuzumab (Herceptin®)-containing regimen - No known brain metastases - Hormone receptor status: - Not specified - Male or female - Performance status - ECOG 0-2 - At least 12 weeks - WBC = 3,000/mm^3 - Absolute neutrophil count = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Bilirubin normal - AST and ALT = 2.5 times upper limit of normal - Creatinine normal - Creatinine clearance = 60 mL/min - No uncontrolled congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia - No severe pulmonary disease requiring oxygen - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No glucose-6-phosphate dehydrogenase (G6PD) deficiency - No other uncontrolled illness - No active or ongoing infection - No history of allergic reaction attributed to compounds of similar chemical or biological composition to 3-AP (Triapine®) or other study agents - No psychiatric illness or social situation that would preclude study compliance - No other malignancy within the past 5 years - See Disease Characteristics - No concurrent immunotherapy - No concurrent routine colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) - See Disease Characteristics - More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) - No prior gemcitabine for metastatic disease - No other concurrent chemotherapy - More than 4 weeks since prior hormonal therapy - More than 4 weeks since prior radiotherapy - No concurrent radiotherapy - Recovered from prior therapy - No concurrent antiretroviral therapy for HIV-positive patients - No other concurrent investigational therapy |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Confirmed response (complete or partial response) | Ninety five percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner. | Up to 6 months | No |
Secondary | Toxicities, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) version 3.0 | Up to 3 years | Yes | |
Secondary | Time to progression | The distribution of time to progression will be estimated using the method of Kaplan-Meier. | Time from registration to the time of progression, assessed up to 3 years | No |
Secondary | Overall survival | The distribution of overall survival will be estimated using the method of Kaplan-Meier. | Time from registration to death due to any cause, assessed up to 3 years | No |
Secondary | Changes in tyrosyl radical and cell-cycle arrest on buccal mucosa | Pre-infusion, 2 and 4.5 hours post-infusion | No | |
Secondary | Changes in R2 messenger ribonucleic acid (mRNA) on protein levels before and after treatment with triapine | Pre-infusion, 2 and 4.5 hours post-infusion | No | |
Secondary | MDR polymorphism on tumor tissue | Baseline | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01987726 -
Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
|
||
Completed |
NCT01881230 -
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
|
Phase 2/Phase 3 | |
Terminated |
NCT01918306 -
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01705340 -
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
Terminated |
NCT01222377 -
Endoscopic Breast Surgery in Treating Patients With Breast Cancer
|
N/A | |
Completed |
NCT00602043 -
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
|
Phase 2 | |
Completed |
NCT00244881 -
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
|
Phase 2 | |
Completed |
NCT00100750 -
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00096109 -
Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT00425672 -
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT00096434 -
Sorafenib in Treating Patients With Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT00057941 -
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT02892734 -
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03213041 -
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT02015559 -
Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
|
Phase 2 | |
Completed |
NCT02728596 -
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
|
N/A | |
Completed |
NCT03364348 -
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
|
Phase 1 | |
Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01672684 -
Phase I: At-Home Support for Rural Women Using Group Video Calling
|
Phase 1 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 |